Abstract:Seventy percent of women with ovarian cancer will develop chemotherapy-resistance to cisplatin. Regardless of the advancements in technology, mortality rates for ovarian cancer have declined only slightly in the last forty years. Therefore, novel and effective second-line therapies for women with ovarian cancer are urgently needed. Previously we showed that Matrix Metalloproteinase 3 (MMP3) expression is upregulated in cisplatin resistant when compared with cisplatin sensitive cells. However, the contribution of MMP3 to cisplatin resistance have not been studied previously. Western blots, ELISAs, and real-time RT-PCR confirmed that the protein and mRNA levels are higher in cisplatin resistant as compared with cisplatin sensitive cells. MMP3 expression levels were also increased by cisplatin treatment of cisplatin resistant cells. Additionally, interrogation of the Kaplan-Meier plotter database showed that ovarian cancer patients with low MMP3 levels live longer than patients with higher MMP3 levels. To understand the impact of targeting MMP3, we employed commercially available chemical inhibitors and small-interference RNA (siRNA) in cell viability, colony formation, invasion, and RNAseq experiments. Notably, MMP3-targeted siRNA significantly reduced cell viability, proliferation, and invasion, particularly when combined with cisplatin treatment. However, the MMP3 chemical inhibitor did not exhibit significant biological effects. RNAseq analysis revealed 415 differentially expressed genes (DEGs) between MMP3-siRNA and negative control (NC)-siRNA groups, as well as 440 DEGs between MMP3-siRNA + cisplatin and NC-siRNA + cisplatin groups. Functional enrichment analysis using Metascape via Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) identified genes associated with potassium and aquaporin mediated transport, clathryn-mediated endocytosis, cell cycle, metabolic processes, cellular response to stress, and extracellular matrix organization. These findings highlight the role of MMP3 upregulation in promoting cisplatin resistance. Citation Format: Mariela Rivera-Serrano, Pablo E. Vivas-Mejía. Unraveling the role of matrix metalloproteinase 3 (mmp3) in cisplatin resistance of ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr B028.

The study of MDRI and MDR3 gene and drug resistant to cisplatin of ovarian cancer cells

Mdr-1 ribozyme in the reversal of multidrug resistance in human ovarian cancer]

Effect of Lung Resistance-Related Protein on the Resistance to Cisplatin in Human Ovarian Cancer Cell Lines.

Identification of a Cisplatin Resistant-Based Prognostic Immune Related Gene Signature in MIBC

The negative feedback between miR‐143 and DNMT3A regulates cisplatin resistance in ovarian cancer

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells

Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.

Mir-509-3p Enhances Platinum Drug Sensitivity in Ovarian Cancer.

Analysis of Micrornas in Drug-Resistant NSCLC Cell Line A549/DDP

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells

Reversal Effect of Ginsenoside Rg3 on Cisplatin-Resistant Human Lung Adenocarcinoma Cell Line(a549ddp) and Its Mechanisms

Abstract B028: Unraveling the role of matrix metalloproteinase 3 (mmp3) in cisplatin resistance of ovarian cancer

Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.

RETRACTED: G-5555 synergized miR-485-5p to alleviate cisplatin resistance in ovarian cancer cells via Pi3k/Akt signaling pathway

Ddifferent expression of multidrug-resistance and apoptosis related genes in human lung adenocarcinoma parental cell line A549 and cisplatin-resistant cell line A549DDP

Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85

Valvoplasty for abnormalities of posterior (mural) cusp of the mitral valve

Study on the relationship between expression levels of ERCC1 mRNA and sensitivity of tumor cells isolated from malignant effusions to cisplatin in vitro

Mir-378A-3p Sensitizes Ovarian Cancer Cells to Cisplatin Through Targeting MAPK1/GRB2.

[Reversal of Multi-Drug Resistance in K562/A02 Cells by Small Interference RNA of Mdr1 Gene].